Ventyx Biosciences (NASDAQ:VTYX) Rating Reiterated by HC Wainwright

Ventyx Biosciences (NASDAQ:VTYX)‘s stock had its “neutral” rating reissued by research analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $6.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 133.46% from the stock’s current price.

VTYX has been the subject of several other reports. Wells Fargo & Company lowered their price objective on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Canaccord Genuity Group lowered their price target on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Ventyx Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $8.29.

Ventyx Biosciences Trading Up 6.6 %

Shares of VTYX opened at $2.57 on Tuesday. The stock has a fifty day moving average price of $2.17 and a 200-day moving average price of $3.12. Ventyx Biosciences has a 12 month low of $1.79 and a 12 month high of $19.04. The firm has a market cap of $181.62 million, a PE ratio of -0.92 and a beta of 0.36.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.12. As a group, research analysts forecast that Ventyx Biosciences will post -2.14 EPS for the current year.

Institutional Trading of Ventyx Biosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Norden Group LLC acquired a new position in shares of Ventyx Biosciences during the 1st quarter worth about $59,000. Acadian Asset Management LLC acquired a new position in shares of Ventyx Biosciences during the second quarter valued at approximately $608,000. Deerfield Management Company L.P. Series C lifted its position in shares of Ventyx Biosciences by 64.6% in the second quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock valued at $13,466,000 after acquiring an additional 2,287,570 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Ventyx Biosciences in the first quarter worth approximately $72,000. Finally, Cubist Systematic Strategies LLC increased its position in shares of Ventyx Biosciences by 165.8% during the second quarter. Cubist Systematic Strategies LLC now owns 149,500 shares of the company’s stock worth $345,000 after purchasing an additional 93,247 shares in the last quarter. Institutional investors and hedge funds own 97.88% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.